A prospective evaluation of intrahisian conduction delay

J. H. McAnulty, Edward Murphy, S. H. Rahimtoola

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    The authors prospectively evaluated 46 patients who had intrahisian conduction delay. 23 had a split His potential and 23 had a prolonged HV interval with a normal QRS complex. In those with a split His, the interval between the two His potentials averaged 32.7 msec (range 9-90 msec); in nine patients this split His was demonstrated only by atrial pacing. The 20 patients from this goup with 1:1 atrioventricular conduction have been followed for an average of 18.1 months (range 2-48 months). All are alive. Three have had syncope, but Holter monitoring revealed no bradyarrhythmias. In the 23 patients with a narrow QRS and prolonged HV interval, the HV interval averaged 73.7 msec (range 57-180 msec). Twelve of these patients received pacemakers at the time of the His bundle study, six had symptomatic atrioventricular block and five had symptomatic sinus pauses. The 11 patients who did not receive pacemakers have been followed for an average of 15.1 months (range 2-44 months). In three with recurrent syncope and 5 with dizziness, monitoring has received no bradyarrhythmias. One patient died from a myocardial infarction without arrhythmias. Further prospective evaluation of patients with intrahisian conduction delay without documented bradyarrhythmias is needed, but with follow-up averaging 17 months and up to 4 years, patients with intrahisian conduction delay and without documented bradyarrhythmias appear not to require prophylactic permanent pacemakers to decrease morbidity or mortality.

    Original languageEnglish (US)
    Pages (from-to)1035-1039
    Number of pages5
    JournalCirculation
    Volume59
    Issue number5
    StatePublished - 1979

    Fingerprint

    Bradycardia
    Syncope
    Bundle of His
    Ambulatory Electrocardiography
    Atrioventricular Block
    Dizziness
    Cardiac Arrhythmias
    Myocardial Infarction
    Morbidity
    Mortality

    ASJC Scopus subject areas

    • Physiology
    • Cardiology and Cardiovascular Medicine

    Cite this

    McAnulty, J. H., Murphy, E., & Rahimtoola, S. H. (1979). A prospective evaluation of intrahisian conduction delay. Circulation, 59(5), 1035-1039.

    A prospective evaluation of intrahisian conduction delay. / McAnulty, J. H.; Murphy, Edward; Rahimtoola, S. H.

    In: Circulation, Vol. 59, No. 5, 1979, p. 1035-1039.

    Research output: Contribution to journalArticle

    McAnulty, JH, Murphy, E & Rahimtoola, SH 1979, 'A prospective evaluation of intrahisian conduction delay', Circulation, vol. 59, no. 5, pp. 1035-1039.
    McAnulty JH, Murphy E, Rahimtoola SH. A prospective evaluation of intrahisian conduction delay. Circulation. 1979;59(5):1035-1039.
    McAnulty, J. H. ; Murphy, Edward ; Rahimtoola, S. H. / A prospective evaluation of intrahisian conduction delay. In: Circulation. 1979 ; Vol. 59, No. 5. pp. 1035-1039.
    @article{193e0c945ae0412da907b5bdb6705c47,
    title = "A prospective evaluation of intrahisian conduction delay",
    abstract = "The authors prospectively evaluated 46 patients who had intrahisian conduction delay. 23 had a split His potential and 23 had a prolonged HV interval with a normal QRS complex. In those with a split His, the interval between the two His potentials averaged 32.7 msec (range 9-90 msec); in nine patients this split His was demonstrated only by atrial pacing. The 20 patients from this goup with 1:1 atrioventricular conduction have been followed for an average of 18.1 months (range 2-48 months). All are alive. Three have had syncope, but Holter monitoring revealed no bradyarrhythmias. In the 23 patients with a narrow QRS and prolonged HV interval, the HV interval averaged 73.7 msec (range 57-180 msec). Twelve of these patients received pacemakers at the time of the His bundle study, six had symptomatic atrioventricular block and five had symptomatic sinus pauses. The 11 patients who did not receive pacemakers have been followed for an average of 15.1 months (range 2-44 months). In three with recurrent syncope and 5 with dizziness, monitoring has received no bradyarrhythmias. One patient died from a myocardial infarction without arrhythmias. Further prospective evaluation of patients with intrahisian conduction delay without documented bradyarrhythmias is needed, but with follow-up averaging 17 months and up to 4 years, patients with intrahisian conduction delay and without documented bradyarrhythmias appear not to require prophylactic permanent pacemakers to decrease morbidity or mortality.",
    author = "McAnulty, {J. H.} and Edward Murphy and Rahimtoola, {S. H.}",
    year = "1979",
    language = "English (US)",
    volume = "59",
    pages = "1035--1039",
    journal = "Circulation",
    issn = "0009-7322",
    publisher = "Lippincott Williams and Wilkins",
    number = "5",

    }

    TY - JOUR

    T1 - A prospective evaluation of intrahisian conduction delay

    AU - McAnulty, J. H.

    AU - Murphy, Edward

    AU - Rahimtoola, S. H.

    PY - 1979

    Y1 - 1979

    N2 - The authors prospectively evaluated 46 patients who had intrahisian conduction delay. 23 had a split His potential and 23 had a prolonged HV interval with a normal QRS complex. In those with a split His, the interval between the two His potentials averaged 32.7 msec (range 9-90 msec); in nine patients this split His was demonstrated only by atrial pacing. The 20 patients from this goup with 1:1 atrioventricular conduction have been followed for an average of 18.1 months (range 2-48 months). All are alive. Three have had syncope, but Holter monitoring revealed no bradyarrhythmias. In the 23 patients with a narrow QRS and prolonged HV interval, the HV interval averaged 73.7 msec (range 57-180 msec). Twelve of these patients received pacemakers at the time of the His bundle study, six had symptomatic atrioventricular block and five had symptomatic sinus pauses. The 11 patients who did not receive pacemakers have been followed for an average of 15.1 months (range 2-44 months). In three with recurrent syncope and 5 with dizziness, monitoring has received no bradyarrhythmias. One patient died from a myocardial infarction without arrhythmias. Further prospective evaluation of patients with intrahisian conduction delay without documented bradyarrhythmias is needed, but with follow-up averaging 17 months and up to 4 years, patients with intrahisian conduction delay and without documented bradyarrhythmias appear not to require prophylactic permanent pacemakers to decrease morbidity or mortality.

    AB - The authors prospectively evaluated 46 patients who had intrahisian conduction delay. 23 had a split His potential and 23 had a prolonged HV interval with a normal QRS complex. In those with a split His, the interval between the two His potentials averaged 32.7 msec (range 9-90 msec); in nine patients this split His was demonstrated only by atrial pacing. The 20 patients from this goup with 1:1 atrioventricular conduction have been followed for an average of 18.1 months (range 2-48 months). All are alive. Three have had syncope, but Holter monitoring revealed no bradyarrhythmias. In the 23 patients with a narrow QRS and prolonged HV interval, the HV interval averaged 73.7 msec (range 57-180 msec). Twelve of these patients received pacemakers at the time of the His bundle study, six had symptomatic atrioventricular block and five had symptomatic sinus pauses. The 11 patients who did not receive pacemakers have been followed for an average of 15.1 months (range 2-44 months). In three with recurrent syncope and 5 with dizziness, monitoring has received no bradyarrhythmias. One patient died from a myocardial infarction without arrhythmias. Further prospective evaluation of patients with intrahisian conduction delay without documented bradyarrhythmias is needed, but with follow-up averaging 17 months and up to 4 years, patients with intrahisian conduction delay and without documented bradyarrhythmias appear not to require prophylactic permanent pacemakers to decrease morbidity or mortality.

    UR - http://www.scopus.com/inward/record.url?scp=0018356193&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0018356193&partnerID=8YFLogxK

    M3 - Article

    C2 - 428085

    AN - SCOPUS:0018356193

    VL - 59

    SP - 1035

    EP - 1039

    JO - Circulation

    JF - Circulation

    SN - 0009-7322

    IS - 5

    ER -